Full CoverageTop news
Monthly weight loss drug helps people lose 20% of body weight, trial finds
By Berkeley Lovelace Jr.
Amgen experimental weight-loss drug needs lower dose to limit side effects
By Deena Beasley
ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half
By Elizabeth Eaton
All coverage
New once-a-month drug could treat diabetes and obesity, scientists say
By Vishwam Sankaran
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
By Elaine Chen
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
By Josh Nathan-kazis
The 'Very Tough' Obesity Meeting That Hammered Amgen Stock
By Allison Gatlin
New Amgen obesity drug data disappoint Wall Street
By Jonathan Gardner
First trial of new monthly weight loss jab shows jaw-dropping results compared to Wegovy and Mounjaro
By Callum Jones
New once-a-month drug could treat diabetes and obesity, scientists say
By Vishwam Sankaran
Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year
By Olivia Burke
Spotlight On: Five ways MariTide's dosing, tolerability could keep it buoyant in competitive waters
By Jessica D'Amico
Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment
By Anjalee Khemlani
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
By Vandana Singh
New once-a-month drug could treat diabetes and obesity, scientists say
By Vishwam Sankaran
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
By Josh Nathan-kazis